These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 33668795)

  • 1. Inhibition of PI3K Isoform p110γ Increases Both Anti-Tumor and Immunosuppressive Responses to Aggressive Murine Head and Neck Squamous Cell Carcinoma with Low Immunogenicity.
    Anderson K; Ryan N; Alkhimovitch A; Siddiqui A; Oghumu S
    Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma.
    Oweida A; Lennon S; Calame D; Korpela S; Bhatia S; Sharma J; Graham C; Binder D; Serkova N; Raben D; Heasley L; Clambey E; Nemenoff R; Karam SD
    Oncoimmunology; 2017; 6(10):e1356153. PubMed ID: 29123967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STAT1 inhibits T-cell exhaustion and myeloid derived suppressor cell accumulation to promote antitumor immune responses in head and neck squamous cell carcinoma.
    Ryan N; Anderson K; Volpedo G; Hamza O; Varikuti S; Satoskar AR; Oghumu S
    Int J Cancer; 2020 Mar; 146(6):1717-1729. PubMed ID: 31709529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buparlisib modulates PD-L1 expression in head and neck squamous cell carcinoma cell lines.
    Fiedler M; Schulz D; Piendl G; Brockhoff G; Eichberger J; Menevse AN; Beckhove P; Hautmann M; Reichert TE; Ettl T; Bauer RJ
    Exp Cell Res; 2020 Nov; 396(1):112259. PubMed ID: 32898555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PDK1 Mediates
    Sambandam V; Frederick MJ; Shen L; Tong P; Rao X; Peng S; Singh R; Mazumdar T; Huang C; Li Q; Pickering CR; Myers JN; Wang J; Johnson FM
    Clin Cancer Res; 2019 Jun; 25(11):3329-3340. PubMed ID: 30770351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
    Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
    Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
    Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
    Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
    Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma.
    Kang SH; Keam B; Ahn YO; Park HR; Kim M; Kim TM; Kim DW; Heo DS
    Oncoimmunology; 2019; 8(1):e1515057. PubMed ID: 30546955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
    Tsai MS; Chen WC; Lu CH; Chen MF
    Oral Oncol; 2019 Apr; 91():47-55. PubMed ID: 30926062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective regulation of CD8 effector T cell migration by the p110 gamma isoform of phosphatidylinositol 3-kinase.
    Martin AL; Schwartz MD; Jameson SC; Shimizu Y
    J Immunol; 2008 Feb; 180(4):2081-8. PubMed ID: 18250413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current studies of immunotherapy in head and neck cancer.
    Dogan V; Rieckmann T; Münscher A; Busch CJ
    Clin Otolaryngol; 2018 Feb; 43(1):13-21. PubMed ID: 28464441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts.
    Falasca M; Maffucci T
    Front Physiol; 2014; 5():391. PubMed ID: 25360116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
    Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
    Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.
    Yu GT; Bu LL; Huang CF; Zhang WF; Chen WJ; Gutkind JS; Kulkarni AB; Sun ZJ
    Oncotarget; 2015 Dec; 6(39):42067-80. PubMed ID: 26573233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
    Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma.
    Müller T; Braun M; Dietrich D; Aktekin S; Höft S; Kristiansen G; Göke F; Schröck A; Brägelmann J; Held SAE; Bootz F; Brossart P
    Oncotarget; 2017 Aug; 8(32):52889-52900. PubMed ID: 28881780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.